Shenzhen Kangtai Biological Products (300601.SZ) intends to acquire 51% equity of Beijing Kunyuan for zero yuan, expanding the company's business development space.

Shenzhen Kangtai Biological Products (300601.SZ) announced that the company plans to acquire the 51% equity of Beijing Kunyuan Biotechnology Co., Ltd. (hereinafter referred to as "Beijing Kunyuan") held by the original shareholder at zero cost (corresponding to a subscribed capital of 51 million yuan, with zero paid-in capital), and to achieve consolidation. Considering that the target company was registered and established on March 6, 2026, with a relatively short existence, and the registered capital corresponding to the transferred equity by the trading counterparty has not been paid in, the parties have agreed to price this transaction at zero cost. This acquisition aims to expand the company's business development space, achieve diversified business development, enhance the company's sustainable operating capability, and strengthen the company's core competitive advantages.